Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Gene Therapy News
Clinical Trial Updates for Ophthalmic Candidates, December 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Emerging Companies Pursuing Ophthalmic Indications, December 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
December 2024 Ophthalmic News Briefs
Dutch company Ophtec announced Nov. 18 that it had gained CE marking for its Artiplus phakic IOL. The company said the lens offered a solution for relatively young presbyopes, typically in their ea...
US FDA Grants Orphan Drug Status to AAVantgarde Bio’s Gene Therapy Candidate for Usher1B RP
Italy’s AAVantgarde Bio announced Dec. 2 the US FDA had granted orphan drug designation to its lead gene therapy candidate, AAVB-081, targeting Usher syndrome type 1B retinitis pigmentosa. Orphan d...
EU Grants Orphan Drug Status to Ocugen’s Gene Therapy Candidate for ABCA4-Associated Retinopathies
Ocugen announced Nov. 20 that the European Medicines Agency had granted orphan medicinal product status for OCU410ST, a gene therapy candidate targeting ABCA4-associated retinopathies, including St...
GenSight Submits Updated Data on Lumevoq to Restart Early Access Program in France
Paris-based GenSight Biologics announced Nov. 13 that it had submitted an updated regulatory file for Lumevoq, its gene therapy candidate for Leber hereditary optic neuropathy (LHON), to French reg...
Atsena Licenses LCA1 Gene Therapy Candidate to Nippon Shinyaku for US, Japan
Atsena Therapeutics announced Nov. 13 that it had granted exclusive commercial rights for its Leber congenital amaurosis type 1 (LCA1) gene therapy candidate ATSN-101 to Nippon Shinyaku in the US a...
MeiraGTx to Submit UK Marketing Application for LCA4 Candidate Under ‘Exceptional Circumstances’
MeiraGTx, with offices in London and New York, announced Nov. 13 that it would submit a marketing authorization application in the UK under “exceptional circumstances” for AAV-AIPL1, its gene thera...
Gene Therapies Make Progress Toward Goal of Restoring Sight
Gene therapies again generated buzz at the 2024 AAO meeting—as they have at recent meetings—but perhaps most exciting were reports of a treatment that could partially restore severe vision loss fro...
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering
EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...
The New Opus Genetics Charts a Course to Gene Therapy Approval
Ben Yerxa, PhD, and George Magrath, MD, say they have a way out of the jungle in which ocular gene therapy development has been trapped since the US FDA approved Luxturna in 2017. “You have to be r...
November 2024 Ophthalmic News Briefs
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
US FDA Gives Green Light to Phase I Trial of HuidaGene’s CRISPR RNA-Editing Candidate for Wet AMD
HuidaGene Therapeutics announced Nov. 4 that the US FDA had cleared its investigational new drug (IND) application for a Phase I trial of HG202, a gene therapy candidate targeting wet age-related m...
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name
Ocuphire Pharma announced Oct. 22 that it would acquire Opus Genetics in an all-stock transaction. The combined company will operate under the Opus name and will trade on the Nasdaq under the ticke...
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
October 2024 Ophthalmic News Briefs
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...
Nanoscope Plans to Submit BLA for Optogenetic RP Candidate in Q1-2025
Nanoscope Therapeutics announced Oct. 10 that it had met with the US FDA regarding MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in patients with advanced retiniti...
US FDA Grants Orphan Drug Status to Atsena’s XLRS Gene Therapy Candidate
Atsena Therapeutics announced Sept. 17 that ATSN-201, its gene therapy candidate for X-linked retinoschisis (XLRS), had received the US FDA’s orphan drug designation. The candidate was granted rare...
AAVantgarde Bio Appoints Jayashree Sahni, MD, as Chief Medical Officer
Italy’s AAVantgarde Bio announced Sept. 9 that it had appointed Jayashree Sahni, MD, FRCOphth, EMBA, as chief medical officer. Sahni, a retina specialist, was senior global program clinical head at...
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...
Emerging Companies Pursuing Ophthalmic Indications, September 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
September 2024 Ophthalmic News Briefs
Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...
US FDA Grants Orphan Drug Status to Skyline’s Gene Therapy Candidate for RP
China’s Skyline Therapeutics announced Sept. 3 that the US FDA had granted orphan drug designation to SKG1108, an intravitreal gene therapy candidate for retinitis pigmentosa (RP). SKG1108 is a rec...
Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease
Tern Therapeutics announced its launch Aug. 27, along with closing of a $15 million financing. The company also reported that it had licensed gene therapy candidates RGX-381 and RGX-181 (now design...
Health Canada Gives Green Light to Phase III Trial of Ocugen’s Gene Therapy Candidate for RP
Ocugen announced Aug. 26 that Health Canada had cleared the way for a Canadian Phase III trial of OCU400, a modifier gene therapy candidate for retinitis pigmentosa (RP). Ocugen, of Malvern, Pennsy...
US FDA Grants Rare Pediatric Disease Designation to Atsena’s X-Linked Retinoschisis Gene Therapy Candidate
Atsena Therapeutics announced Aug. 14 that ATSN-201, its gene therapy candidate for X-linked retinoschisis (XLRS), had received the US FDA’s rare pediatric disease designation. XLRS is a monogenic ...
US FDA Grants Rare Pediatric Disease Designation to Opus’ LCA5 Gene Therapy Candidate
Opus Genetics announced Aug. 20 that OPGx-LCA5, its gene therapy candidate for Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene, had received the US FDA’s rare p...
SalioGen Therapeutics Appoints Kali Stasi, MD, PhD, as Chief Medical Officer
SalioGen Therapeutics announced Aug. 19 that it had appointed Kalliopi “Kali” Stasi, MD, PhD, as chief medical officer. SalioGen said Stasi will be responsible for bringing the company’s SGT-1001, ...
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering
MeiraGTx led recent ophthalmic fundraising efforts with a $50 million offering of ordinary shares as it moves forward with its extensive pipeline of gene therapy candidates. Financing announced in ...
Clinical Trial Updates for Ophthalmic Candidates, August 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
August 2024 Ophthalmic News Briefs
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
US FDA Approves Expanded Access Program for Ocugen’s RP Candidate
Ocugen announced Aug. 5 that the US FDA had approved an expanded access program to allow for the treatment of adults with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candi...
Adverum Receives US FDA’s RMAT Designation for Ixo-vec in Wet AMD
Adverum Biotechnologies announced Aug. 1 that Ixo-vec, its intravitreal gene therapy candidate for wet age-related macular degeneration (AMD), had received the US FDA’s regenerative medicine advanc...
Beacon Appoints Lance Baldo, MD, as Chief Executive Officer
Beacon Therapeutics announced July 24 that it had named Lance Baldo, MD, as chief executive officer, effective Aug. 12, 2024. Most recently, Baldo served as chief medical officer at Freenome, an ea...
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
Emerging Companies Pursuing Ophthalmic Indications, July 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Clinical Trial Updates for Ophthalmic Candidates, July 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
July 2024 Ophthalmic News Briefs
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Beacon Will Evaluate Abeona’s AAV204 Capsid for Select Ophthalmic Indications
Beacon Therapeutics will evaluate Abeona Therapeutics’ patented AAV204 capsid for potential gene therapies for select ophthalmic indications, the companies announced July 11. AAV204, a novel AAV ca...
US FDA Gives Green Light to Trial of 4DMT’s Gene Therapy Candidate for GA
4D Molecular Therapeutics announced June 24 that the US FDA had cleared its investigational new drug application for a Phase I clinical trial of 4D-175, an intravitreal gene therapy candidate targe...
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer
Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...
June 2024 Ophthalmic News Briefs
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
Opus Genetics, Abu Dhabi to Collaborate on Retinal Gene Therapies in UAE
Opus Genetics and Abu Dhabi’s Department of Health announced June 5 that they had agreed to collaborate on the development of gene therapies for patients with rare inherited retinal diseases in the...
Regenxbio Appoints Simpson as President, CEO; Co-founder Mills Transitions to Chairman
Regenxbio announced June 12 that its chief operating officer, Curran Simpson, had been appointed president and chief executive officer. He will also join the board of directors. Co-founder Kenneth ...
US FDA Gives Green Light to Trial of Avirmax’ Gene Therapy Candidate for Wet AMD with PCV
Avirmax Biopharma announced May 30 that the US FDA had cleared its investigational new drug application for a Phase I/IIa clinical trial of its intravitreal gene therapy candidate targeting wet age...
2024 ARVO Meeting Sets Attendance Record, Showcases Novel Treatment Approaches
The 2024 meeting of the Association for Research in Vision and Ophthalmology set a record as the largest ARVO meeting ever. The 11,631 registered attendees passed the old record of 10,224 set in Va...
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering
RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Ophthalmic Companies Use ARVO Meeting to Boost Research
Many companies participate in ARVO’s annual meeting to catch the attention of external researchers and propel their research program or clinical trials forward. Two such companies in 2024 were John...
Clinical Trial Updates for Ophthalmic Candidates, May 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Clinical Trial Updates for Ophthalmic Candidates , April 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Nanoscope Reports Positive Results for RP Optogenetic Therapy
Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monother-apy to restore vision i...
SalioGen Selects Gene Therapy Candidate to Develop for Stargardt
SalioGen Therapeutics announced April 17 that it had chosen a development candidate, SGT-1001, for the treatment of Stargardt disease. SGT-1001 is being developed as a one-time, non-viral gene ther...
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate
Ocugen announced April 8 that the US FDA had cleared the company’s investigational new drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy candidate for r...
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024
Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in...
Clinical Trial Updates for Ophthalmic Candidates, March 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Oculogenex’ Preclinical Retinal Gene Therapy Heads to Space for Study in Mice
Oculogenex, a California company developing a regenerative gene therapy for age-related macular degeneration (AMD), is sending its preclinical work into space. The company’s gene therapy candidate ...
Emerging Companies Pursuing Ophthalmic Indications, March 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Oculogenex’ Preclinical Retinal Gene Therapy Heads to Space with Mouse Model
Oculogenex, a California company developing a regenerative gene therapy for age-related macular degeneration (AMD), is sending its preclinical work into space. The company’s gene therapy candidate ...
France’s PulseSight Therapeutics Launches to Advance Non-viral Retinal Gene Therapies
France’s PulseSight Therapeutics, developing non-viral ophthalmic gene therapies, launched Feb. 28 with an undisclosed seed financing from Pureos Bioventures and ND Capital. A spokeswoman for Pulse...
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Wet AMD Trial
4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...
February 2024 Ophthalmic News Briefs
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Trial for Wet AMD
4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...
Ascidian’s Stargardt Candidate is First RNA Exon Editor to Gain FDA’s Green Light for Trial
Ascidian Therapeutics announced Jan. 29 that the US FDA had cleared a Phase I/II clinical trial for its ACDN-01 RNA exon editor for Stargardt disease and other ABCA4 retinopathies. It’s the first g...
Clinical Trial Updates for Ophthalmic Candidates, January 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Janssen Purchases Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million
Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercializa-tion of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx r...
January 2024 Ophthalmic News Briefs
Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...
US FDA Grants Rare Pediatric Disease Designation to Atsena’s LCA1 Gene Therapy Candidate
Atsena Therapeutics announced Jan. 16 that its gene therapy candidate for Leber congenital amaurosis 1, ATSN-101, had received the US FDA’s rare pediatric disease designation. The candidate had alr...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
Kriya Therapeutics announced Jan. 5 that it had added to its pipeline a gene therapy candidate for thyroid eye disease (TED). TED is an autoimmune condition that can cause proptosis (eye bulging) a...
4DMT Receives US FDA’s RMAT Designation for Wet AMD Gene Therapy Candidate
4D Molecular Therapeutics announced Dec. 21 that 4D-150, its intravitreal gene therapy candidate targeting wet age-related macular degeneration (AMD), had received the US FDA’s regenerative medicin...
SpliceBio Appoints Aniz Girach, MD, as Chief Medical Officer
Spain’s SpliceBio announced Jan. 3 that it had appointed Aniz Girach, MD, as chief medical officer. SpliceBio’s protein splicing platform offers the potential to address diseases where the genetic ...
Janssen Buys Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million
Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercialization of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx re...
Emerging Companies Pursuing Ophthalmic Indications, December 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
December 2023 Ophthalmic News Briefs
Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...
Generation Bio Drops Retinal Candidates, Cuts Workforce
Generation Bio, of Cambridge, Massachusetts, reported Nov. 29 that it would stop advancing its pipeline of retinal candidates as it redefines its strategic priorities and reduces its workforce by 4...
Emerging Companies Pursuing Ophthalmic Indications, November 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
November 2023 Ophthalmic News Briefs
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...
Atsena Receives FDA’s RMAT Designation for LCA1 Gene Therapy Candidate
Atsena Therapeutics announced Nov. 14 that its gene therapy candidate for Leber congenital amaurosis 1, ATSN-101, had received the US FDA’s regenerative medicine advanced therapy (RMAT) designation...
Regenxbio Says it Will Cut Staff, Realign Pipeline Priorities to Extend Cash Runway
Regenxbio announced in its Q3-2023 financial statement on Nov. 8 that it would cut its workforce by approximately 15 percent while prioritizing three gene therapy candidates with the largest commer...
Ascidian Raises $40 Million in Series A Funding, Appoints Michael Ehlers as Interim President, CEO
Ascidian Therapeutics announced Nov. 8 that it had raised $40 million in Series A extension funding from life sciences venture capital company Apple Tree Partners. Ascidian, of Boston, Massachusett...
Chinese Regulators Give Green Light to Skyline for Trial of Gene Therapy Candidate for Wet AMD
China’s Skyline Therapeutics announced Oct. 19 that the National Medical Products Administration had cleared its investigational new drug application for a clinical trial of SKG0106, a one-time int...
Futures Forums Cater to Companies that Can’t Gain Limelight Elsewhere, Co-founder Says
Kuldev Singh, MD (US), co-founder of Europe’s annual Ophthalmology Futures Forums (OFF), told Market Scope in October that he takes pride in the group’s record of giving “people with new ideas who ...
Acquisitions and OUS Investments Drive Ophthalmic Deals in Third Quarter of 2023
Ophthalmic deals in Q3-2023 reached nearly $2.8 billion and involved 22 transactions. This compares with $6.9 billion from 24 transactions in Q2-2023 and $1.0 billion from 20 transactions in Q3-202...
Clinical Trial Updates for Ophthalmic Candidates, October 2023
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
October 2023 Ophthalmic News Briefs
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
Emerging Companies Pursuing Ophthalmic Indications, October 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
SpliceBio, Spark Therapeutics to Collaborate on Gene Therapy Targeting Inherited Retinal Disease
Spain’s SpliceBio announced Oct. 17 that it had signed an agreement with Spark Therapeutics to utilize SpliceBio’s protein splicing platform to develop a gene therapy for an undisclosed inherited r...
Kriya Licenses Everads’ Suprachoroidal Delivery Technology for Gene Therapy Candidates Targeting Complement Cascade
Israel’s Everads Therapy announced Sept. 27 that it had entered into an agreement with Kriya Therapeutics to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ supracho...
ProQR’s Deal with Théa to Acquire Ophthalmic Assets is Terminated
Netherlands-based ProQR Therapeutics announced Sept. 27 that a deal with France’s Laboratoires Théa to acquire ProQR’s late-stage ophthalmic assets had been terminated. Théa had agreed in August 20...
Nanoscope Appoints Samuel Barone, MD, as Chief Medical Officer
Nanoscope Therapeutics, of Dallas, announced Sept. 21 that it had appointed Samuel Barone, MD, as chief medical officer. Barone was most recently chief medical officer at Gemini Therapeutics, prior...
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue
Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...
Novartis Drops Gene Therapy Candidate for GA Acquired in Gyroscope Deal
UK life sciences investment firm Syncona reported on Sept. 11 that Novartis had decided to discontinue development of geographic atrophy (GA) gene therapy candidate GT005, which it acquired in Dece...
Clinical Trial Updates for Ophthalmic Candidates, September 2023
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
September 2023 Ophthalmic News Briefs
Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...
Novartis Discontinues Development of GA Gene Therapy Candidate Acquired in Gyroscope Deal
UK life sciences investment firm Syncona reported on Sept. 11 that Novartis had decided to discontinue development of geographic atrophy (GA) gene therapy candidate GT005, which it acquired in Dece...
Otsuka, ShapeTX Will Collaborate on Ocular Gene Therapy Candidates
Japan’s Otsuka Pharmaceutical and ShapeTX announced Sept. 7 that they would collaborate to develop intravitreally delivered adeno-associated virus (AAV) gene therapy candidates for ocular diseases,...
Neurophth Gets Green Light from Australian Regulators for Trial of Ophthalmic Gene Therapy Candidate
Neurophth Therapeutics announced Sept. 6 that the Australian Therapeutic Goods Administration had cleared its gene therapy candidate NFS-05 for clinical trials targeting autosomal dominant optic at...
EMA Gives Green Light to Phase Ib Trial of ViGeneron’s Gene Therapy Candidate for RP
Germany’s ViGeneron announced Aug. 22 that the European Medicines Agency (EMA) had approved its clinical trial application for VG901, a gene therapy candidate targeting CNGA1-associated retinitis p...
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....
Gene Therapy Developer Intergalactic Therapeutics Lays Off All Employees
Boston-headquartered Intergalactic Therapeutics has laid off all its employees and is exploring options, the Boston Business Journal reported Aug. 1. Intergalactic was developing a non-viral gene t...
US FDA Grants Rare Pediatric Disease Designation to HuidaGene’s RPE65 Gene Therapy Candidate
HuidaGene Therapeutics announced Aug. 7 that the US FDA had given rare pediatric disease designation to HG004, a gene therapy candidate for inherited retinal dystrophies associated with the RPE65 m...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.